FIELD: biomedicine.
SUBSTANCE: invention relates to biomedicine, particularly molecular and clinical oncology. Disclosed is a method for prediction of ovarian cancer metastasis based on six long non-coding RNA genes MEG3, ZNF667-AS1, ZEB1-AS1, GAS5, SEMA3B-AS1 and KCNK15-AS1 by detecting methylation of at least four markers.
EFFECT: disclosed method enables predicting the formation of metastases in ovarian cancer with high sensitivity and specificity.
1 cl, 1 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING BREAST CANCER METASTASIS BASED ON SET OF LONG NON-CODING RNA GENES | 2022 |
|
RU2807480C1 |
| METHOD FOR DIAGNOSING OVARIAN CANCER BASED ON A SET OF GENES OF LONG NON-CODING RNA | 2021 |
|
RU2779550C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BASED ON A SET OF LONG NON-CODING RNA GENES | 2022 |
|
RU2795976C1 |
| METHOD FOR DIAGNOSING OVARIAN CANCER BASED ON A GROUP OF microRNA GENES | 2018 |
|
RU2703399C1 |
| METHOD FOR FORECASTING METASTASIS OF OVARIAN CANCER BASED ON MICRORNA GENE GROUP | 2016 |
|
RU2666911C2 |
| METHOD OF PREDICTING METASTASIS OF STOMACH CANCER TUMORS | 2021 |
|
RU2806432C2 |
| METHOD OF DIAGNOSIS OF CLEAR CELL RENAL CELL CARCINOMA AND METHOD FOR PREDICTION OF METASTASIS BASED ON MIRNA GENES GROUP | 2017 |
|
RU2683251C1 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| TEST SYSTEM “miR-M-SCREEN” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH COLORECTAL CANCER BASED ON THE LEVEL OF miR-26a AND miR-143 MICRO-RNA IN BLOOD PLASMA | 2022 |
|
RU2786386C1 |
| SYSTEM OF MARKERS BASED ON GROUP OF MICRORNA GENES FOR DIAGNOSTICS OF NON-SMALL-CELL LUNG CANCER INCLUDING EPIDERMOID CANCER AND ADENOCARCINOMA | 2012 |
|
RU2507268C1 |
